Table 3.

Factors associated with detection of NVP resistance in infants HIV-infected between 6 weeks and 6 months of age.*

Factor		N (%)	Relative Risk (95 %CI [IQR])	P-value
ARV exposure from study	NVP arm	6/8 (75.0 %)	12.8 (1.8 – 89.0)	0.001
regimen	Placebo arm	1/17 (5.9 %)
ARV exposure for PMTCT	Maternal ZDV prophylaxis:		0.5 (0.2 – 1.8)	0.355
	Yes	4/18 (22.2 %)
	No	3/7 (42.9 %)
	Maternal 3TC prophylaxis:		0.4 (0.1 – 2.9)	0.626
	Yes	1/7 (5.9 %)
	No	6/18 (75.0 %)
	Infant ZDV prophylaxis:		2.3 (0.3 – 16.1)	0.626
	Yes	6/18 (33.3 %)
	No	1/7 (14.3 %)
ARV exposure for maternal or infant treatment	Maternal HAART by 6 months postpartum		7.0 (2.5 – 20.0)	0.003
	Yes	4/4 (100.0 %)
	No	3/21 (14.2 %)
	Infant HAART by 6 months of age		--	1.000
	Yes	0/2 (0.0 %)
	No	7/23 (30.4 %)
Other factors	HIV-infected by 3 months		0.4 (0.1 – 3.0)	0.626
	Yes	1/7 (14.3 %)
	No	6/18 (75.0 %)
	HIV subtype		1.9 (0.3 – 12.8)	0.637
	C	6/19 (31.6 %)
	A	1/6 (16.7 %)